UK-based clinical-stage biotechnology company TC BioPharm (Holdings) plc (NASDAQ: TCBP) announced on Wednesday that it has opened a new site at Guys and St. Thomas Hospital in the ACHIEVE UK Trial of TCB008.

The open-label, phase II study is aimed at assessing the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease.

Guys and St. Thomas, a London-based hospital, has an oncology clinic and cell therapy clinical team. Principal Investigator on the trial is Dr Hugues de Lavallade, who has more than 10 years of experience as a consultant haematologist with a special interest in myeloid disorders.

Alison Bracchi, executive vice president of Clinical at TC BioPharm, said: "The progression of the ACHIEVE clinical trial since the dose increase earlier this year continues to be very positive with strong enrolment and remains on schedule for data in the first half of 2025. We are thrilled with the positive feedback from clinicians and the wider AML community as we continue recruitment and activate new sites for this important trial, and we feel fortunate to be partnering with several centres of excellence to help us deliver on our goal of offering new hope and an alternative treatment of seriously ill AML patients."